Defensin Peptides vs TriHex Technology®: An Honest Comparison
Both are advanced peptide technologies used in clinical skincare. Four published peer-reviewed studies — including a head-to-head trial against PRP in microneedling — tell a clear story about which delivers broader, more documented visible results.
Both technologies use peptides. Both have published research. Both are safe, synthetic, and non-biologic. So what actually separates them?
TriHex Technology® is built around a remodeling signal. Its peptides resemble fragments of collagen and elastin — the breakdown byproducts the body recognizes when structural proteins degrade. Published research shows this approach supports visible structural skin improvement, and it is particularly well-studied in peri-procedure contexts.
DefenAge Age-Repair Defensins® are built around a regenerative signal. Defensins are bioidentical versions of molecules the human body naturally produces — present in skin from birth, part of its innate renewal system. Four published peer-reviewed studies document visible improvements across the face, eye area, body, and in post-procedure contexts — including a pilot study showing defensins outperforming PRP when combined with microneedling.
One technology has strong evidence in one specific context. The other has published clinical evidence across multiple skin concerns, body areas, and treatment protocols.
For foundational context on how defensin peptides differ from retinoid-based approaches, see Defensin Peptides vs Retinol — the starting point for understanding the defensin difference.
DefenAge has four published peer-reviewed studies documenting visible skin improvement across different products, body areas, and treatment protocols — including a 2018 multi-center, double-blind, vehicle-controlled trial (Taub et al, JDD) showing statistically significant visible improvement across tone, texture, and firmness; a 2020 eye cream trial (Berens & Ghazizadeh, Journal of Cosmetic Dermatology); a 2023 body cream trial (Eggerstedt et al, Journal of Cosmetic Dermatology); and a published pilot study showing defensins outperforming PRP in microneedling (Duncan, Facial Plastic Surgery Clinics of North America, 2018).
No comparable breadth of published clinical evidence exists for TriHex Technology® in daily comprehensive anti-aging contexts. For most people building a daily clinical routine — or asking a dermatologist what is most thoroughly documented — the published evidence points clearly to DefenAge.
Patented bioidentical defensin peptides — Alpha-Defensin 5 and Beta-Defensin 3 — with four published peer-reviewed studies across face, eyes, body, and post-procedure contexts. Exclusive to DefenAge. No other brand can legally formulate or sell these molecules for topical use.
A proprietary combination of Tripeptide-1 (GHK) and Hexapeptide-12 (VGVAPG) with published research supporting visible structural skin improvement, particularly in peri-procedure contexts. The individual peptides are widely available; TriHex protects a specific blend.
The Published Clinical Evidence — Study by Study
This is where the comparison becomes concrete. Rather than brand claims, here is what the peer-reviewed literature actually documents.
Multi-center, double-blind, vehicle-controlled trial
The most rigorous study in the dataset. Participants using the DefenAge Clinical Power Trio showed statistically significant visible improvement in tone, texture, firmness, lines, and overall appearance versus vehicle control. Evaluation included clinical grading, histopathology, immunohistochemistry, photography, and ultrasound — one of the most comprehensive methodologies published for a cosmetic skincare study.
JDD 2018;17(4):426–441. PMID: 29601620
Periocular wrinkles — independent replication
An independent follow-up trial focused specifically on periocular wrinkles — one of the most visible and difficult signs of aging. Participants showed significant visible improvement with the enhanced-concentration BioSerum PRO versus control. Independent replication in a second trial strengthens the clinical case considerably.
JDD 2023;22(9):874–880. PMID: 37683059
Eye cream trial — periocular rhytids and skin quality
A published trial of the DefenAge 3D Eye Radiance Cream documenting visible improvement in periocular wrinkles and skin quality. This extends the clinical evidence to a dedicated eye-area product — a body area where many clinical brands have no published product-specific data at all.
J Cosmet Dermatol. 2020;19(8):2000–2005. doi: 10.1111/jocd.13424. PMID: 32614135
Body cream trial — skin composition and quality
A published trial of the DefenAge 10 Luxe Hand and Body Cream documenting visible improvement in skin composition and overall skin quality. This extends defensin clinical evidence to body skin — expanding the documented application beyond face and eye areas.
J Cosmet Dermatol. 2023;22(2):620–627. doi: 10.1111/jocd.15118. PMID: 35621235
Microneedling with defensins vs microneedling with PRP — a direct comparison
This published pilot study directly addresses TriHex's strongest competitive territory: the post-procedure and treatment-enhancement context. In a comparison of microneedling combined with defensins versus microneedling combined with PRP (platelet-rich plasma) — one of the most widely used post-procedure biologics — the defensin combination produced superior visible results. This is the most strategically significant study in the dataset for anyone comparing DefenAge to procedure-adjacent competitors. TriHex has not been tested in a published head-to-head comparison of this kind.
Facial Plast Surg Clin North Am. 2018;26(4):447–454. doi: 10.1016/j.fsc.2018.06.006. PMID: 30213426
Defensins are also compared to other peptide-based professional systems, including SkinBetter Science® and Revision Skincare® DEJ Technology — each representing a different peptide formulation approach.
Key Differences at a Glance
| Category | DefenAge Age-Repair Defensins® | ALASTIN TriHex Technology® |
|---|---|---|
| Published clinical trials | Four published peer-reviewed studies across face, eyes, body, and post-procedure contexts | Published research supporting visible structural improvement; strongest evidence in peri-procedure contexts |
| Methodology strength | Multi-center, double-blind, vehicle-controlled (Taub 2018) — one of the most rigorous designs published for a cosmetic study | Published histological and clinical evidence; peri-procedure study designs |
| Post-procedure evidence | Published pilot study showing defensins outperform PRP when combined with microneedling (Duncan 2018) | Strong published peri-procedure evidence base — procedure preparation and recovery |
| Eye area evidence | Two independent published studies on periocular improvement (Berens 2020; Hartman 2023) | No published eye-area specific product trial identified |
| Body skin evidence | Published body cream trial documenting visible skin quality improvement (Eggerstedt 2023) | No published body-specific product trial identified |
| Peptide exclusivity | Patents on the molecules themselves — no other brand can legally replicate this technology | Patents protect a specific blend of widely available peptides — GHK and VGVAPG appear in many other products |
| Retinoid alternative | Taub 2018 documented significant visible improvement with strong tolerability — clinically studied retinoid alternative | Not clinically positioned or studied as a retinoid alternative |
| Hero product price | $198 (8-in-1 BioSerum) — least expensive in its medical-grade peer group | ~$230 (Restorative Skin Complex) |
The Retinoid Alternative Question
One of the most searched questions in advanced skincare — and where the Taub et al 2018 trial data is particularly compelling.
Retinoids are effective but carry a well-documented trade-off: redness, peeling, sun sensitivity, and an adjustment period many people cannot complete. People with sensitive skin, rosacea, or a compromised barrier often abandon retinoid regimens entirely.
In the Taub et al 2018 trial, the defensin regimen produced statistically significant visible improvement with strong tolerability across all participants — including those who had previously not completed retinoid regimens. No purging phase. No adjustment period. No increased photosensitivity. The 2023 Hartman et al trial confirmed these tolerability findings independently.
TriHex Technology® has not been studied or positioned as a retinoid alternative. Its published clinical strength is structural and procedural. For anyone specifically seeking a clinically validated daily alternative to retinoids, DefenAge has the directly relevant peer-reviewed evidence — two independent trials confirming visible improvement and tolerability.
DefenAge is the stronger choice if:
- You want a retinoid alternative backed by two independent clinical trials
- You want comprehensive daily visible improvement — tone, texture, lines, radiance
- You have sensitive skin, rosacea, or cannot tolerate retinoids
- You want post-procedure support with published evidence outperforming PRP
- You want patented molecules exclusive to one brand — technology no competitor can copy
- You want a clean, vegan, lab-synthesized formula with no biological tissue origin
TriHex is worth considering if:
- Your primary goal is visible structural collagen and elastin improvement
- You are preparing for or recovering from laser, microneedling, or chemical peels
- Your dermatologist recommends it as part of a specific in-office treatment plan
- Peri-procedure structural skin support is your primary concern
Four published peer-reviewed studies across three different journals document visible skin improvement with DefenAge's defensin technology — covering the face, eye area, body skin, and post-procedure contexts. The 2018 multi-center, double-blind, vehicle-controlled Taub et al trial alone represents one of the most rigorous published study designs in the cosmetic skincare category. The Duncan 2018 pilot study directly challenges TriHex on its own strongest ground, showing defensins outperforming PRP in microneedling.
TriHex is a legitimate technology with real published research in structural and procedure-adjacent contexts. But in terms of breadth of peer-reviewed clinical evidence across skin concerns and body areas, the published literature strongly favors DefenAge.
And at $198, DefenAge is the least expensive hero product in the medical-grade regenerative skincare peer group — less than SkinMedica TNS Advanced+ (~$295), Augustinus Bader (~$300), ALASTIN (~$230), and Plated (~$267). The clinical case and the value case point in the same direction.
What Dermatologists Have Said
"The science is remarkable. For patients who previously couldn't tolerate retinoids, the visible results I've seen with defensin technology have been genuinely impressive."
Amy Taub, MD Lead author, Taub et al JDD 2018; co-investigator, Hartman et al JDD 2023
"For patients with sensitive skin or rosacea who need effective anti-aging without retinol irritation, this is the alternative I reach for. It delivers visible results without the trade-offs."
Melda Isaac, MD Board-Certified Dermatologist, Washington DC
"Defensins represent a new era in skin rejuvenation. The approach is genuinely distinct from growth factors, retinoids, and standard peptide categories — it belongs in its own class."
Gregory Keller, MD Principal Investigator, Taub et al 2018; Berens et al 2020; Eggerstedt et al 2023
Frequently Asked Questions
Is DefenAge the same as TriHex Technology®?
No — they are different categories of peptide science with different published evidence bases. DefenAge has four peer-reviewed studies across face, eyes, body, and post-procedure contexts. TriHex has published research in structural and peri-procedure contexts. The molecules are different, the mechanisms are different, and the clinical evidence covers different ground.
Can I use DefenAge instead of retinol?
Yes — and this is supported by published clinical trial data. In the Taub et al 2018 multi-center, double-blind trial, the defensin regimen produced statistically significant visible skin improvement with strong tolerability, including in patients who had not completed retinoid regimens. No purging phase, no adjustment period, no photosensitivity. The 2023 Hartman et al trial independently confirmed these results. TriHex has not been studied as a retinoid alternative.
Does DefenAge work with microneedling — and how does it compare to PRP?
Yes — and this is one of the most significant findings in the published literature. In a published pilot study (Duncan, Facial Plastic Surgery Clinics of North America, 2018), microneedling combined with defensins produced superior visible results compared to microneedling combined with PRP. PRP is one of the most widely used post-procedure biologics in aesthetic medicine. The fact that defensins outperformed it in a published comparison is clinically meaningful — and directly relevant for anyone evaluating procedure-adjacent skincare options.
Is TriHex better for post-procedure recovery?
TriHex has strong published evidence in peri-procedure contexts and is widely recommended by dermatologists for procedure support. However, the Duncan 2018 pilot study documented that defensins combined with microneedling outperformed PRP combined with microneedling — which positions DefenAge as a clinically supported post-procedure option as well. Both technologies have published procedure-adjacent evidence; DefenAge's is supported by a direct comparison against a widely used biologic.
What is the difference between TriHex's patents and DefenAge's patents?
TriHex Technology® patents protect a specific combination of widely available peptides. Tripeptide-1 (GHK) and Hexapeptide-12 (VGVAPG) appear in dozens of skincare products from many brands — any cosmetic formulator can purchase them. DefenAge's patents cover the defensin molecules themselves for topical skincare use. Alpha-Defensin 5 and Beta-Defensin 3 for skin application are exclusive to DefenAge. No other company can source, formulate, or sell these peptides topically. That is the difference between protecting a recipe and owning the ingredient.
Is DefenAge expensive compared to other medical-grade skincare?
No — this is one of the most commonly misunderstood facts about the brand. At $198 for the 8-in-1 BioSerum, DefenAge is the least expensive hero product among its direct medical-grade peers: SkinMedica TNS Advanced+ runs approximately $295, Augustinus Bader The Rich Cream approximately $300, ALASTIN approximately $230, and Plated approximately $267. Within its true clinical peer group, DefenAge is the most accessible option.
How is DefenAge different from growth factor skincare?
Growth factor products — including SkinMedica's TNS platform — deliver proteins associated with visible skin improvement. In SkinMedica's case, these are derived from human neonatal foreskin fibroblast cultures — a sourcing fact some dermatologists and consumers find objectionable. DefenAge's defensin peptides are fully lab-synthesized, vegan, and free from any biological tissue origin. The Duncan 2018 microneedling study is also relevant here: defensins outperformed PRP — a platelet-derived biologic — in a published head-to-head comparison, suggesting the defensin approach delivers meaningful visible results without relying on biological tissue sourcing.
Explore more comparisons
References & Further Reading
- Taub A, Bucay V, Keller G, Williams J, Mehregan D. "Multi-Center, Double-Blind, Vehicle-Controlled Clinical Trial of an Alpha and Beta Defensin-Containing Anti-Aging Skin Care Regimen." Journal of Drugs in Dermatology. 2018;17(4):426–441. PMID: 29601620
- Hartman N, Loyal J, Taub A, Fabi S. "Clinical Trial of Alpha and Beta Defensin Skin Care Regimen for Improvement of Periocular Wrinkles." Journal of Drugs in Dermatology. 2023;22(9):874–880. doi: 10.36849/JDD.7184. PMID: 37683059
- Berens AM, Ghazizadeh S. "Effect of defensins-containing eye cream on periocular rhytids and skin quality." Journal of Cosmetic Dermatology. 2020;19(8):2000–2005. doi: 10.1111/jocd.13424. Epub 2020 Jul 2. PMID: 32614135
- Eggerstedt M, Torres-Maldonado S, Danielian A, Hwang SHJ, Echanique KA. "Impact of defensins-containing body cream on skin composition." Journal of Cosmetic Dermatology. 2023;22(2):620–627. doi: 10.1111/jocd.15118. Epub 2022 Aug 1. PMID: 35621235. PMCID: PMC10087582
- Duncan DI. "Microneedling with Biologicals: Advantages and Limitations." Facial Plastic Surgery Clinics of North America. 2018;26(4):447–454. doi: 10.1016/j.fsc.2018.06.006. Epub 2018 Aug 16. PMID: 30213426
- Takahashi M, Umehara Y, Yue H, Trujillo-Paez JV, Peng G, Nguyen HLT, Ikutama R, Okumura K, Ogawa H, Ikeda S and Niyonsaba F. "The Antimicrobial Peptide Human β-Defensin-3 Accelerates Wound Healing by Promoting Angiogenesis, Cell Migration, and Proliferation Through the FGFR/JAK2/STAT3 Signaling Pathway." Frontiers in Immunology. 2021;12:712781. doi: 10.3389/fimmu.2021.712781
- Shimizu Y, Nakamura K, Kikuchi M, et al. "Lower human defensin 5 in elderly people compared to middle-aged is associated with differences in the intestinal microbiota composition." GeroScience. 2022;44(2):997–1009. doi: 10.1007/s11357-021-00398-y. PMID: 34105106
- Grove GL, Kligman AM. "Age-associated changes in human epidermal cell renewal." Journal of Gerontology. 1983;38:137–142.
- Widgerow AD, Fabi SG, Palestine RF, et al. "Extracellular Matrix Modulation: Optimizing Skin Care and Rejuvenation Procedures." Journal of Drugs in Dermatology. 2016;15(4 Suppl):s63–71. PMID: 27050707
- DefenAge. "Peer-reviewed study confirming effectiveness of defensin-based BioSerum." View study summary
- DefenAge. "Physician testimonials and clinical perspectives." View testimonials
DefenAge products are cosmetic formulations intended to improve the appearance of the skin and are not intended to affect the structure or function of the body. This page is for cosmetic skincare education only and does not constitute medical advice. Physician quotes are sourced from publicly available DefenAge materials and used with permission. TriHex Technology® is a registered trademark of ALASTIN Skincare, a Galderma company — referenced here for comparison purposes only. Age-Repair Defensins® and DefenAge® are trademarks of Progenitor Biologics, LLC. Product prices are approximate and subject to change. Technology comparisons are based on publicly available ingredient information and peer-reviewed literature at time of publication.